Methods for preparing N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropylox… Grant US-11840515-B2 United States of America 12 Dec 2023
Pimavanserin alone or in combination for use in the treatment of Alzheimer's disease… Grant US-11464768-B2 United States of America 11 Oct 2022
Combination of pimavanserin and cytochrome P450 modulators Grant US-11191757-B2 United States of America 07 Dec 2021
Pimavanserin for treating impulse control disorder Grant US-11135211-B2 United States of America 05 Oct 2021
Methods for preparing N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropylox… Grant US-10981870-B2 United States of America 20 Apr 2021
Methods for preparing N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropylox… Grant US-10981871-B2 United States of America 20 Apr 2021
Combination of pimavanserin and cytochrome P450 modulators Grant US-10953000-B2 United States of America 23 Mar 2021
Combination of pimavanserin and cytochrome P450 modulators Grant US-10517860-B2 United States of America 31 Dec 2019
5-HT2A SEROTONIN RECEPTOR INVERSE AGONISTS OR ANTAGONISTS FOR USE IN REDUCING AMYLOID-BETA… Application WO-2017172757-A1 World Intellectual Property Organisation (WIPO) 05 Oct 2017